Table 3.
Current clinical trials about universal CAR T cells
| CAR target | Gene-editing technology | Locus of knock-out | Diseases | Phase | R&D Unit | Study location | NCT ID |
|---|---|---|---|---|---|---|---|
| CD19 | TALENs | TCR and CD52 | B-ALL | 1 | Servier Group company | America, Europe | NCT02808442 NCT02735083 NCT02746952 |
| CD19 | CRISPR/Cas9 | TRAC and HLA-I | ALL and NHL | 1/2 | Shanghai Bioray Laboratory Inc. | China | NCT03229876 |
| CD19 | CRISPR/Cas9 | TRAC and B2M | B cell leukemia and lymphoma | 1/2 | Chinese PLA General Hospital | China | NCT03166878 |
| CD19 | CRISPR/Cas9 | TCR and CD52 | RR DLBCL | 1 | Nanjing Bioheng Biotech Co., Ltd | China | NCT04026100 |
| CD123 | TALENs | TCR and CD52 | RR and Newly Diagnosed High-risk AML | 1 | Cellectis S.A. | Europe | NCT04106076 NCT03190278 |
| CD123 | TALENs | TCR and CD52 | RR BPDCN | 1 | Cellectis S.A. | America | NCT03203369 |
| BCMA | CRISPR/Cas9 | TRAC and HLA-I | Multiple Myeloma | 1/2 | Shanghai Bioray Laboratory Inc. | China | NCT03752541 |
NHL, Non-Hodgkin lymphoma; RR, refractory or relapsed; DLBCL, diffuse large B-cell lymphoma; BPDCN, blastic plasmacytoid dendritic cell neoplasm.